In Reply
- PMID: 30045198
- DOI: 10.1097/AOG.0000000000002770
In Reply
Comment on
-
Occult Gynecologic Cancer in Women Undergoing Hysterectomy or Myomectomy for Benign Indications.Obstet Gynecol. 2018 Apr;131(4):642-651. doi: 10.1097/AOG.0000000000002521. Obstet Gynecol. 2018. PMID: 29528920
-
Occult Gynecologic Cancer in Women Undergoing Hysterectomy or Myomectomy for Benign Indications.Obstet Gynecol. 2018 Aug;132(2):519. doi: 10.1097/AOG.0000000000002769. Obstet Gynecol. 2018. PMID: 30045197 No abstract available.
References
-
- Desai VB, Wright JD, Schwartz PE, Jorgensen EM, Fan L, Litkouhi B, et al. Occult gynecologic cancer in women undergoing hysterectomy or myomectomy for benign indications. Obstet Gynecol 2018;131:642–51.
-
- Maggard-Gibbons M. The use of report cards and outcome measurements to improve the safety of surgical care: the American College of Surgeons national surgical quality improvement program. BMJ Qual Saf 2014;23:589–99.
-
- U.S. Food and Drug Administration. FDA updated assessment of the use of laparoscopic power morcellators to treat uterine fibroids. Available at: https://www.fda.gov/downloads/MedicalDevices/ProductsandMedicalProcedure.... Retrieved July 2, 2018.
-
- Hartmann KE, Fonnesbeck C, Surawicz T, Krishnaswami S, Andrews JC, Wilson JE, et al. Management of uterine fibroids. Comparative Effectiveness review No. 195. AHRQ Publication No. 17(18)-EHC028-EF. Rockville (MD): Agency for Healthcare Research and Quality; 2017.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical